$5M Private Placement Led by CEO and Insiders Funds Path to Q1 2027 FDA Filing
CNXU sits 25% above its 52-week low of $3.05 on elevated volume (2.5× avg).
Summary
Conexeu closed a roughly $5M private placement at $3.00 per unit, each unit carrying one share and a 24-month warrant struck at $3.00. The round was led by existing holders, including CEO Miles Harrison and Chief Commercial Officer David Bogart, with $250,000 of management and director subscriptions held in escrow pending Nasdaq 5635(c) stockholder approval. The raise is a lifeline for a company that reported a $7.7M quarterly loss with only $2.0M of cash and a going concern warning on Sept. 14. Proceeds go to manufacturing scale-up, regulatory testing and preclinical work supporting the planned Q1 2027 510(k) submission for Ten Minute Tissue, following the Oct. 6 update that scaled-up CXU batches met specifications. The $3.00 unit price sits below the $3.80 market price, and the warrants add future dilution, but insider-led demand at that level is a meaningful vote of confidence. Watch for the 8-K and resale registration statement, plus the stockholder vote needed to release the escrowed $250,000.
At the time of this announcement, CNXU was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $111.4M. The 52-week trading range was $3.05 to $18.79. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.